# SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

> **NCT06210438** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 24 (estimated)

## Conditions studied

- TNBC
- Brain Metastasis

## Interventions

- **DRUG:** SHR-A1921 + Bevacizumab

## Key facts

- **NCT ID:** NCT06210438
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06210438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06210438, "SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06210438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*